Omeros Corporation $OMER Shares Newly Acquired by Corient Private Wealth LP

Corient Private Wealth LP acquired a new stake in Omeros Corporation (NASDAQ:OMER) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 659,730 shares of the biopharmaceutical company’s stock, valued at approximately $6,274,000. Corient Private Wealth LP owned approximately 0.91% of Omeros at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in shares of Omeros in the second quarter worth approximately $1,846,000. Jupiter Topco LLC acquired a new position in Omeros in the 2nd quarter valued at approximately $290,000. Ancora Advisors LLC acquired a new stake in shares of Omeros during the 2nd quarter valued at $1,605,000. Legal & General Group Plc acquired a new stake in shares of Omeros during the 2nd quarter valued at $425,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Omeros during the 2nd quarter valued at $180,000. Institutional investors own 48.79% of the company’s stock.

Insider Buying and Selling at Omeros

In other Omeros news, CAO David Borges sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the chief accounting officer owned 5,906 shares in the company, valued at $111,918.70. This trade represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Cable sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the transaction, the director owned 35,067 shares of the company’s stock, valued at approximately $646,986.15. This represents a 29.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 105,906 shares of company stock worth $1,989,705 in the last three months. 10.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OMER. Weiss Ratings cut Omeros from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Cantor Fitzgerald raised Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 price target for the company in a research note on Tuesday, September 22nd. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Omeros Stock Down 0.3%

Omeros stock traded down $0.05 during mid-day trading on Tuesday, reaching $19.38. The company had a trading volume of 392,591 shares, compared to its average volume of 1,687,282. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of 15.14 and a beta of 2.60. The company has a 50 day moving average of $16.40 and a 200-day moving average of $13.11. Omeros Corporation has a 52 week low of $4.05 and a 52 week high of $21.24.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, analysts predict that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.